| pubmed-article:21236563 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21236563 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:21236563 | lifeskim:mentions | umls-concept:C0025914 | lld:lifeskim |
| pubmed-article:21236563 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:21236563 | lifeskim:mentions | umls-concept:C0527841 | lld:lifeskim |
| pubmed-article:21236563 | lifeskim:mentions | umls-concept:C0027627 | lld:lifeskim |
| pubmed-article:21236563 | lifeskim:mentions | umls-concept:C0475463 | lld:lifeskim |
| pubmed-article:21236563 | lifeskim:mentions | umls-concept:C0018270 | lld:lifeskim |
| pubmed-article:21236563 | lifeskim:mentions | umls-concept:C1332820 | lld:lifeskim |
| pubmed-article:21236563 | lifeskim:mentions | umls-concept:C1705880 | lld:lifeskim |
| pubmed-article:21236563 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:21236563 | pubmed:dateCreated | 2011-2-2 | lld:pubmed |
| pubmed-article:21236563 | pubmed:abstractText | The chemokine granulocyte chemotactic protein (GCP)-2/CXCL6 promotes tumor growth as angiogenesis inducer and neutrophil chemoattractant. The neutralizing capacity and specificity of monoclonal mouse anti-murine (mu)GCP-2/CXCL6 antibodies were evidenced by granulocyte chemotaxis and signaling assays. The half-life of the non-antigenic antibody in the blood circulation was approximately 15 days. The titers remained constant upon weekly injection. Tumor growth and lymphogenic metastases of human melanoma over-expressing muGCP-2 were reduced in mice treated with anti-muGCP-2. Moreover, the drop in muGCP-2 antibody titer correlated with the melanoma tumor size. Taken together, we show that functional blocking of GCP-2 inhibits tumor growth and metastases. | lld:pubmed |
| pubmed-article:21236563 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21236563 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21236563 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21236563 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21236563 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21236563 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21236563 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21236563 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:21236563 | pubmed:issn | 1872-7980 | lld:pubmed |
| pubmed-article:21236563 | pubmed:author | pubmed-author:Van DammeJoJ | lld:pubmed |
| pubmed-article:21236563 | pubmed:author | pubmed-author:OpdenakkerGhi... | lld:pubmed |
| pubmed-article:21236563 | pubmed:author | pubmed-author:Van... | lld:pubmed |
| pubmed-article:21236563 | pubmed:author | pubmed-author:StruyfSofieS | lld:pubmed |
| pubmed-article:21236563 | pubmed:author | pubmed-author:UyttenhoveCat... | lld:pubmed |
| pubmed-article:21236563 | pubmed:author | pubmed-author:Van... | lld:pubmed |
| pubmed-article:21236563 | pubmed:author | pubmed-author:BerghmansNele... | lld:pubmed |
| pubmed-article:21236563 | pubmed:author | pubmed-author:VerbekeHannel... | lld:pubmed |
| pubmed-article:21236563 | pubmed:copyrightInfo | Copyright © 2010 Elsevier Ireland Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:21236563 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21236563 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:21236563 | pubmed:volume | 302 | lld:pubmed |
| pubmed-article:21236563 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21236563 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21236563 | pubmed:pagination | 54-62 | lld:pubmed |
| pubmed-article:21236563 | pubmed:meshHeading | pubmed-meshheading:21236563... | lld:pubmed |
| pubmed-article:21236563 | pubmed:meshHeading | pubmed-meshheading:21236563... | lld:pubmed |
| pubmed-article:21236563 | pubmed:meshHeading | pubmed-meshheading:21236563... | lld:pubmed |
| pubmed-article:21236563 | pubmed:meshHeading | pubmed-meshheading:21236563... | lld:pubmed |
| pubmed-article:21236563 | pubmed:meshHeading | pubmed-meshheading:21236563... | lld:pubmed |
| pubmed-article:21236563 | pubmed:meshHeading | pubmed-meshheading:21236563... | lld:pubmed |
| pubmed-article:21236563 | pubmed:meshHeading | pubmed-meshheading:21236563... | lld:pubmed |
| pubmed-article:21236563 | pubmed:meshHeading | pubmed-meshheading:21236563... | lld:pubmed |
| pubmed-article:21236563 | pubmed:meshHeading | pubmed-meshheading:21236563... | lld:pubmed |
| pubmed-article:21236563 | pubmed:meshHeading | pubmed-meshheading:21236563... | lld:pubmed |
| pubmed-article:21236563 | pubmed:meshHeading | pubmed-meshheading:21236563... | lld:pubmed |
| pubmed-article:21236563 | pubmed:meshHeading | pubmed-meshheading:21236563... | lld:pubmed |
| pubmed-article:21236563 | pubmed:meshHeading | pubmed-meshheading:21236563... | lld:pubmed |
| pubmed-article:21236563 | pubmed:meshHeading | pubmed-meshheading:21236563... | lld:pubmed |
| pubmed-article:21236563 | pubmed:meshHeading | pubmed-meshheading:21236563... | lld:pubmed |
| pubmed-article:21236563 | pubmed:meshHeading | pubmed-meshheading:21236563... | lld:pubmed |
| pubmed-article:21236563 | pubmed:meshHeading | pubmed-meshheading:21236563... | lld:pubmed |
| pubmed-article:21236563 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21236563 | pubmed:articleTitle | Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis. | lld:pubmed |
| pubmed-article:21236563 | pubmed:affiliation | Rega Institute for Medical Research, Laboratory of Molecular Immunology, K.U.Leuven, Leuven, Belgium. | lld:pubmed |
| pubmed-article:21236563 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21236563 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:6372 | entrezgene:pubmed | pubmed-article:21236563 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:21236563 | lld:entrezgene |
